Clinicopathologic Conference, Neurosarcoidosis
NEJM 374:1966-1975, Case 15-2016, 2016
Nocardiosis of the Central Nervous System
Medicine 93:19-32, Anagnostou, T.,et al, 2014
Progressive Multifocal Leukoencephalopathy in Patients with Sarcoidosis
Neurol 82:1307-1313, Jamilloux, Y.,et al, 2014
Opportunistic Infections of the Retina in Patients with Aquaporin-4 Antibody Disease
JAMA Neurol 71:1429-1432, George, J.S.,et al, 2014
Stiff-Man Syndrome and Variants
Arch Neurol 69:230-238, McKeon,A.,et al, 2012
Autoimmune encephalitis
BMJ 342:d1918, Irani, S.R.,et all, 2011
A Case of Hashimoto Encephalopathy Clinical Manifestation, Imaging, Pathology, Treatment, and Prognosis
The Neurologist 17:141-143, Zhao, W.,et al, 2011
Encephalitis and antibodies to synaptic and neuronal cell surface proteins
Neurol 77:179-189, Lancaster, E.,et al, 2011
Autoimmune Limbic Encephalitis with GAD Antibodies
The Neurohospitalist 1:178-181, Finelli, P.F., 2011
Neurosacrcoidosis: Presentations and Management
Neurologist 16:2-15, Terushkin,V.,et al, 2010
Anti-N-Methyl-D-Aspartate Receptor (NHMDAR) Encephalitis in Children and Adolescents
Ann Neurol 66:11-18,1, Florance,N.R.,et al, 2009
Diagnosis and Treatment of Neuromyelitis Optica
The Neurologist 13:2-11, Wingerchuk,D.M., 2007
Clinicopath Conf., Multifocal Motor Neuropathy With Conduction Block
NEJM 357: 2707-2715, Case 40-2007, 2007
What Went Wrong in the Natalizumab Trials?
Lancet 367:706-709, Langer-Gould,A.&Steinman,L., 2006
Reversible Posterior Leukoencephalopathy Syndrome
Intern Med J 35:83-90, Stott,V.L.,et al, 2005
Update on Susacs Syndrome
Curr Opin Neurol 18:311-314, Gross,M. &Eliashar,R., 2005
Clinicopath Conf., Progessive Multifocal Leukoencephalopathy
NEJM 350:1884-1893, Case 14-2004, 2004
The Neurologic Complications of Scleromyxedema
Medicine 80:313-319, Berger,J.R.,et al, 2001
Progressive Multifocal Leukoencephalopathy in a 15-Year-Old Boy with Scleroderma and Secondary Amyloidosis
Pediatrics 103:1475-1479, Hahn,J.S.,et al, 1999
Retinocochleocerebral Vasculopathy
Medicine 77:12-40, Petty,G.W.,et al, 1998
Ocular Myasthenia:A Protean Disorder
Survey of Ophthalmology 39:169-210, Weinberg,D.A.,et al, 1994
Polymyositis, Dermatomyositis, and Inclusion-Body Myositis
NEJM 325:1487-1498, Dalakas,M.C., 1991
Clinicopath Conf
Primary (Granulomatous) Angiitis of Central Nervous System, Case Record 8-1989, NEJM 320:514-5249., , 1989
Granulomatous Angiitis of the Central Nervous System:Protean Manifestations and Response to Treatment
JNNP 51:1126-1133, Koo,E.H.&Massey,E.W., 1988
Clinical Presentation, Investigation Findings, and Outcomes of IgG4-Related Pachymeningitis,A Systematic Review
JAMA Neurol 82:193-199, Terrim,S.,et al, 2025
Inebilizumab for Treatment of IgG4-Related Disease
NEJM 392:1168-1177, Stone,J.H.,et al, 2025
Beyond Glucocorticoids for IgG4-Related Disease
NEJM 392:1232-1233, Spiera,R., 2025
Clinicopathologic Features, Pathogenesis, and Treatment of Monoclonal Gammopathy-Associated Myopathies
Neurol 105:213101, Soontrapa,P.,et al, 2025
Posterior Reversible Encephalopathy Syndrome
NEJM 388:2171-2178, Geocadin,R.G., 2023
Neuromyelitis Optica Spectrum Disorder
NEJM 387:631-639, Wingerchuk, D.M. & Lucchinetti, C.F., 2022
A 47-Year-Old With Headache, Vertigo, and Double Vision
Neurol 97:e535-e539, Frey, J.,et al, 2021
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum
Ann Neurol 87:659-669, Dubey, D.,et al, 2020
Acute Encephalitis in Immunocompetent Adults
Lancet 393:702-716, Venkatesan, A.,et al, 2019
Validation of Clinicoradiological Criteria for the Diagnosis of Cerebral Amyloid Angiopathy-Related Inflammation
JAMA Neurol 73:197-202, Auriel, E.,et al, 2016
Fulminant Central Nervous System Nocardiosis in a Patient Treated with Alemtuzumab for Relapsing-Remitting Multiple Sclerosis
JAMA Neurol 73:757-759, Penkert, H.,et al, 2016
A Case of Subacute Cognitive Decline in a 76-year-old Man
Neurol 87:e124-e128, MacLellan, A.,et al, 2016
Myasthenia Gravis
NEJM 375:2570-2581, Gilhus, N.E.,et al, 2016
Inflammatory Muscle Diseases
NEJM 372:1734-1747, Dalakas, M.C., 2015
Inflammatory Cerebral Amyloid Angiopathy, Amyloid-B-Related Angiitis, and Primary Angiitis of the Central Nervous System
Stroke 46:e210-e213, Moussaddy, A.,et al, 2015
Mycophenolate Mofetil in Multiple Sclerosis: A Multicentre Retrospective Study on 344 Patients
JNNP 85:279-283,246, Michel, L.,et al, 2014
Progressive Visuospatial Problems in a 71-Year-Old Man
Neurol 83:e6-e10, Symmonds, M.,et al, 2014
Central Nervous System Neuronal Surface Antibody Associated Syndromes: Review and Guidelines for Recognition
JNNP 83:638-645, Zuliani,L.,et al, 2012
Risk of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
NEJM 366:1870-1880,1938, Bloomgren, G.,et al, 2012
Adult Primary Central Nervous System Vasculitis
Lancet 380:767-777, Salvarani, C.,et al, 2012
The use of rituximab in myasthenia gravis and Lambert--Eaton myasthenic syndrome
JNNP 82:671-673, Maddison, P.,et al, 2011
Use and monitoring of low dose rituximab in myasthenia gravis
JNNP 82:659-663, Blum, S., et al, 2011
Efficacy and Safety of Mitoxantrone in Patients with Highly Relapsing Neuromyelitis Optica
Arch Neurol 68:473-479, Kim, S.H.,et al, 2011